Skip to main content

Table 1 Frequency spectrum of hTERT promoter mutations across diverse cancer types

From: Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies

Cancer type Mutation frequency (%) Reference
Bladder carcinoma 47–85 [100]
Renal pelvic carcinoma 60–64 [101]
Urothelial carcinoma 47 [102]
Hepatocellular carcinoma 24–59 [6, 103]
Melanoma 67–85 [3]
Skin basal cell carcinoma 39–74 [104]
Thyroid cancer (papillary and poorly differentiated carcinomas) 50–52 [105]
Myxoid liposarcoma 74–79 [106]
Glioblastoma 28–84 [6, 48]
Medulloblastoma 19–42 [107]
Oligoastrocytoma
Oligodendroglioma
25–53
72
[6, 107]
[44]
Breast cancer, colorectal cancer, medullary thyroid carcinoma, ovarian cancer, esophageal adenocarcinoma, acute myeloid leukemia, chronic lymphoid leukemia, pancreatic cancer, prostate cancer, testicular carcinoma, uterine cervix cancer 0–5 [48, 104]